BMS 986231

Drug Profile

BMS 986231

Alternative Names: BMS-986231; CXL 1427; HNO Donor

Latest Information Update: 16 Jun 2017

Price : $50

At a glance

  • Originator Cardioxyl Pharmaceuticals
  • Developer Bristol-Myers Squibb
  • Class Heart failure therapies
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute heart failure

Most Recent Events

  • 26 May 2017 Bristol-Myers Squibb completes a phase I trial in Healthy volunteers in USA (NCT02932969)
  • 01 Jan 2017 Bristol-Myers Squibb initiates the phase IIb STANDUP AHF trial for Acute heart failure in USA (IV, infusion) (NCT03016325)
  • 12 Oct 2016 Bristol-Myers Squibb plans a phase I trial in Healthy volunteers in USA (IV) (NCT02932969)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top